Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort
IMPORTANCE: Israel was among the first countries to launch a large-scale COVID-19 vaccination campaign, and quickly vaccinated its population, achieving early control over the spread of the virus. However, the number of COVID-19 cases is now rapidly increasing, which may indicate that vaccine protection decreases over time.
OBJECTIVE: To determine whether time elapsed since the second BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) injection is significantly associated with the risk of post-vaccination COVID-19 infection.
DESIGN: This is a retrospective cohort study performed in a large state-mandated health care organization in Israel.
PARTICIPANTS: All fully vaccinated adults who have received a RT-PCR test between May 15, 2021 and July 26, 2021, at least two weeks after their second vaccine injection were included. Patients with a history of past COVID-19 infection were excluded.
MAIN OUTCOME AND MEASURE: Positive result for the RT-PCR test.
RESULTS: The cohort included 33,993 fully vaccinated adults, 49% women, with a mean age of 47 years (SD, 17 years), who received an RT-PCR test for SARS-CoV-2 during the study period. The median time between the second dose of the vaccine and the RT-PCR test was 146 days, interquartile range [121-167] days. 608 (1.8%) patients had positive test results. There was a significantly higher rate of positive results among patients who received their second vaccine dose at least 146 days before the RT-PCR test compared to patients who have received their vaccine less than 146 days before: odds ratio for infection was 3.00 for patients aged over 60 (95% CI 1.86-5.11); 2.29 for patients aged between 40 and 59 (95% CI 1.67-3.17); and 1.74 for patients aged between 18 and 39 (95% CI 1.27-2.37); P<0.001 in each age group.
CONCLUSIONS AND RELEVANCE: In this large population study of patients tested for SARS-CoV-2 by RT-PCR following two doses of mRNA BNT162b2 vaccine, we observe a significant increase of the risk of infection in individuals who received their last vaccine dose since at least 146 days ago, particularly among patients older than 60.
Errataetall: | |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
---|---|
Enthalten in: |
medRxiv : the preprint server for health sciences - (2021) vom: 05. Aug. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Israel, Ariel [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 28.04.2022 published: Electronic UpdateIn: BMJ. 2021 Nov 24;375:e067873. - PMID 34819275 Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1101/2021.08.03.21261496 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM329455079 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM329455079 | ||
003 | DE-627 | ||
005 | 20231225205145.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2021.08.03.21261496 |2 doi | |
028 | 5 | 2 | |a pubmed24n1098.xml |
035 | |a (DE-627)NLM329455079 | ||
035 | |a (NLM)34401882 | ||
035 | |a (PII)2021.08.03.21261496 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Israel, Ariel |e verfasserin |4 aut | |
245 | 1 | 0 | |a Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 28.04.2022 | ||
500 | |a published: Electronic | ||
500 | |a UpdateIn: BMJ. 2021 Nov 24;375:e067873. - PMID 34819275 | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a IMPORTANCE: Israel was among the first countries to launch a large-scale COVID-19 vaccination campaign, and quickly vaccinated its population, achieving early control over the spread of the virus. However, the number of COVID-19 cases is now rapidly increasing, which may indicate that vaccine protection decreases over time | ||
520 | |a OBJECTIVE: To determine whether time elapsed since the second BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) injection is significantly associated with the risk of post-vaccination COVID-19 infection | ||
520 | |a DESIGN: This is a retrospective cohort study performed in a large state-mandated health care organization in Israel | ||
520 | |a PARTICIPANTS: All fully vaccinated adults who have received a RT-PCR test between May 15, 2021 and July 26, 2021, at least two weeks after their second vaccine injection were included. Patients with a history of past COVID-19 infection were excluded | ||
520 | |a MAIN OUTCOME AND MEASURE: Positive result for the RT-PCR test | ||
520 | |a RESULTS: The cohort included 33,993 fully vaccinated adults, 49% women, with a mean age of 47 years (SD, 17 years), who received an RT-PCR test for SARS-CoV-2 during the study period. The median time between the second dose of the vaccine and the RT-PCR test was 146 days, interquartile range [121-167] days. 608 (1.8%) patients had positive test results. There was a significantly higher rate of positive results among patients who received their second vaccine dose at least 146 days before the RT-PCR test compared to patients who have received their vaccine less than 146 days before: odds ratio for infection was 3.00 for patients aged over 60 (95% CI 1.86-5.11); 2.29 for patients aged between 40 and 59 (95% CI 1.67-3.17); and 1.74 for patients aged between 18 and 39 (95% CI 1.27-2.37); P<0.001 in each age group | ||
520 | |a CONCLUSIONS AND RELEVANCE: In this large population study of patients tested for SARS-CoV-2 by RT-PCR following two doses of mRNA BNT162b2 vaccine, we observe a significant increase of the risk of infection in individuals who received their last vaccine dose since at least 146 days ago, particularly among patients older than 60 | ||
650 | 4 | |a Preprint | |
700 | 1 | |a Merzon, Eugene |e verfasserin |4 aut | |
700 | 1 | |a Schäffer, Alejandro A |e verfasserin |4 aut | |
700 | 1 | |a Shenhar, Yotam |e verfasserin |4 aut | |
700 | 1 | |a Green, Ilan |e verfasserin |4 aut | |
700 | 1 | |a Golan-Cohen, Avivit |e verfasserin |4 aut | |
700 | 1 | |a Ruppin, Eytan |e verfasserin |4 aut | |
700 | 1 | |a Magen, Eli |e verfasserin |4 aut | |
700 | 1 | |a Vinker, Shlomo |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2021) vom: 05. Aug. |w (DE-627)NLM310900166 |7 nnns |
773 | 1 | 8 | |g year:2021 |g day:05 |g month:08 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.08.03.21261496 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2021 |b 05 |c 08 |